The direct medical costs of colorectal cancer in Iran; Analyzing the patient's level data from a cancer specific hospital in Isfahan

International Journal of Preventive Medicine

Volumn 3, Issue 12, 2012, Pages 887-892

  Davari, Majid ^a   Maracy, Mohammad R ^b   Emami, Mohamad H ^c   Taheri, Diana ^c   Aslani, Abolfazl ^b   Givi, Mahshid ^b   Massah, Saeid ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Cost analysis; Iran

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER STAGING; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; PATIENT ASSESSMENT; REVIEW;

EID: 84871638747     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: 10.4103/2008-7802.104861     Document Type: Review

References (27)

1. Azizi F, Hatami H, Janghorbani M. Epidemiology and control of current diseases in Iran. Tehran: Khosravi Publisher; 2004. p. 158-96.
2. Doherty GM. Current consult surgery. NewYork: Lange medical books/McGraw-Hill;2004.
3. Longo DL, Fauci AS. Harrison's Gastroenterology and Hepatology. NewYork: McGraw-Hill; 2010.
4. Shadi Kolahdoozan AS, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med 2010;13:143-6.
5. Amini M, Khadivi R. Direct cost of medicine due to diabetic nephropathy in NIDDM patients at Isfahan. Iran J Endocrinol Metab 1999;1:215-23.
6. Amini M, Khadivi R, Haghighi S. Study on economic costs of diabetes in NIDDM patients at Isfahan. Iran J Endocrinol Metab2002;4:97-104.
7. Byford S, Torgerson DJ, Raftery J. Economic note: Cost of illness studies. BMJ 2000;320:1335.
8. Drummond MF, Sculpher MJ, Torrance GW, O' Brien BJ, Storddart GL. Methods of economic evalluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
9. Jansman FG, Postma M. Costs of chemotherapy in the treatment of colorectal cancer. Eur J Health Econ 2006;7:145-6.
10. Sobin LH, Wittenking C. TNM classification of malignant tumours. 6thed. NewYork: Wiley-Liss; 2002.
11. Davari M. Economic challenges of the Iranian health system. Health Information Management. Health Inf Manag 2012;8915-7.
12. Vahid Dastjerdi M. The inflation rate in health care section is more than 50 percent Fars News Agency, 2012.
13. Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 2008;14:717-25.
14. Karimi Zarchi AA, Saadat A, Jalalian HR, Esmaeili M. Epidemiology and survival analysis of colorectal cancer and its related factors. Kowsar Med J2011;15:239-43.
15. Safaei Zadeh A, Moghimi Dehkordi B, Fatemi SR, Zali MR. Epidemiology of colorectal cancer; the study of the recorded cases between 1990 and 2007. Zahedan J Res Med Sci (TABIB-E-SHARGH);2007.
16. Emami M, Fatemi A, Farajzadegan Z, Movahed AS. Epidemiology of colorectal cancer in Isfahan province. Govaresh J 2005;10:134-9.
17. Sohrab Pour AA. The cancer in developing countries. Novin Pezeshki (New Medicine) 2012;13:660.
18. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: Aworldwide population-based study (CONCORD). Lancet Oncol 2008;9:730-56.
19. Zali MR, editor. Congress Message The second national congress in gastro-intestinal cancers. The Iranian Association of Gastroenterology and Hepatology (IAGH): Tehran; 2007.
20. Adami HO, Hunter DJ, Trichopoulos D. Text book of cancer epidemiology. USA: Oxford University Press; 2002.
21. Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2012. p. 2-8.
22. Mousavi SM, Gouya MM, Ramazani R, Davanlou D, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2008;20:556-63.
23. Tilson L, Sharp L, Usher C, Walsh C, O'Ceilleachair A, Stuart C, et al. Cost of care for colorectal cancer in Ireland: Ahealth care payer perspective. Eur J Health Econ 2012:13:5111-24.
24. Davari M, Haycox A, Walley T. Issues related to health care financing in Iran; is privatization a good solution? Iran J Public Health 2012;41:14-21.
25. Davari M, Maracy M, Aslani A, Tabatabei M. Cost-effectiveness analysis of cetuximab for treatmnet of colorectal cancer patients: Asystematic review. Isfahan: Isfahan University of Medical Sciences; 2012.
26. Dorudi S, Steele RJ, McArdle CS. Surgery for colorectal cancer. Br Med Bull 2002;64:101-18.
27. Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. JClin Oncol 2004;22:3475-84.